According to study, “Psychotic Major Depression
Global Clinical Trials Review, H1, 2018”
some of the major companies that are currently working in the psychotic major
depression are Pop Test LLC, Merck & Co Inc, The Lundbeck Foundation, Takeda
Pharmaceutical Co Ltd, Syri Ltd, Pfizer Inc, Johnson & Johnson, Eli Lilly
and Co, Corcept Therapeutics Inc, AstraZeneca Plc.
Psychotic major depressive disorder is a common mental
disorder that can negatively affect many areas of someone’s life. It impacts
mood and behavior as well as various physical functions, including appetite and
sleep. People with major depression often lose interest in activities they once
enjoyed and have trouble performing everyday activities.Depression is one of
the most common mental disorders worldwide. There are a number of depression
subtypes, and there has been much debate about how to most accurately capture
and organize the features and subtypes of major depression.
Psychotic major depression is characterized by two features,
which are; mood-congruent and mood-incongruent. A mood-congruent psychotic feature
means the content of the hallucinations and delusion is consistent with typical
depressive themes: it may include feelings of personal inadequacy, guilt or
worthlessness whereas mood-incongruent psychotic features means the content of
hallucinations and delusions don’t involve typical depressive themes. It is a
serious illness during which a person suffers from the combination of depressed
mood and psychosis, with the psychosis commonly manifesting itself as
nihilistic type delusions, with the belief that bad things are about to happen.
Unfortunately, until recently, the treatment of psychotic depression has not
been studied to the same extent as other psychiatric disorders with similar
prevail, and remains an underdiagnosed and undertreated psychiatric disorder.
Some symptoms of psychotic major depression are agitation, anxiety,
constipation, hypochondria, insomnia, intellectual impairment, physical
immobility and delusions or hallucinations etc.Sadness, hopelessness, guilt and
irritability are feelings of psychotic major depressions. There are some
medications of psychotic major depression are used to stabilize the person’s
mood, which are; antidepressants and antipsychotic medications. Antipsychotic
drugs affect neurotransmitters that allow communication between nerve cells in
areas of the brain that regulate the ability to perceive and organize
information about the world. Some antipsychotic medications are risperidone,
olanzapine, quetiapine, aripiprazole, cariprazine, and asenapine. Blood test,
urine test and brain scan are some tests involved in psychotic depression.
Psychotic depression is usually treated in a hospital, using
antidepressant and antipsychotic medications. When depression symptoms are
severe, electroconvulsive therapy (ECT) may be used to bring about rapid
relief.ECT therapy is a psychiatric treatment in which seizures are
electrically induced in patients to provide relief from mental disorders, also
known as electroshock therapy. One another therapy is also used psychotic major
depression i.e. cognitive behavioural therapy (CBT).CBT is a type of
psychotherapy that modifies thought patterns to change moods and behaviors.
Some drugs are used in psychotic major depression such as olanzapine,
quetiapine and risperidone. These drugs take several months to be most
effective.
Most treatment guidelines recommend either the combination
of an antidepressant with an antipsychotic or ECT for the treatment of an acute
episode of unipolar psychotic depression. The optimal maintenance treatment
after a person responds to either the antidepressant/antipsychotic combination
or the ECT is unclear particularly as it pertains to length of time the patient
needs to take the antipsychotic medication. Little is known regarding the
optimal treatment of a patient with bipolar disorder who has an episode of
psychotic depression or the clinical characteristics of responders to
medication treatments vs ECT treatments.
To know more,
click on the link below:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
